Skip to main content

Patient-derived xenograft (PDX) models

Improve your therapeutic efficacy predictions with our fully characterized patient-derived xenografts (PDX) representing multiple histotypes.
Connect with a representative

PDX models play a crucial role in accelerating drug development by providing a more clinically relevant platform for preclinical testing. They enhance the likelihood of success in clinical trials by better predicting how therapies will perform in human patients, ultimately leading to the development of more effective and personalized treatment for cancer.
 

Growing portfolio of recently collected PDXs to advance personalized medicine approaches

Choose from our growing portfolio of fully characterized PDX models representing multiple histotypes. Our models are recently collected providing a more accurate reflection of human cancer biology compared to older or less relevant models. Plus, we continue to grow our portfolio by adding models consistently.

Cancer types include:

  • Brain
  • Breast
  • Cholangio/Bile duct
  • Colorectal
  • Gastric
  • Head and neck
  • Lung
  • Neuroendocrine
  • Ovarian
  • Pancreatic
  • Sarcoma
  • Skin

  • Fully characterized, disease-relevant PDXs representing multiple histotypes

  • Extensive molecular and gene expression characterization in addition to treatment history

  • Deep scientific capabilities and an enterprise team that supported 77% of the oncology drugs approved by the FDA in 2023 

Fully characterized for enhanced utility and improved translatability

Proper characterization ensures your model data is reproducible, reliable and high quality. It identifies the predictive power of the drug response and therapeutic outcome and increases the likelihood that findings from preclinical studies will translate into effective therapies for patients.

Our models have extensive molecular and pharmacological characterization, including treatment history. From the genomic, molecular and phenotypic data to tumor growth curves, histopathology data and relevant patient information to access the data to make informed decisions.


Maximize the insights gained from PDX Models

Our optimized PDX engraftment procedures and modern technologies, such as multi-omics, digital spatial analysis and biodistribution, boost the utilization of PDX models and provide comprehensive insights into their molecular landscape. To utilize the unique genomic features of PDX models obtained from patients of diversified cancer subtypes, stages and treatment backgrounds, we offer a broad range of ex vivo analysis capabilities . Additionally, we offer a variety of therapeutic approaches including adoptive cell therapies and combination therapies with radiation and radiopharmaceuticals to support your oncology research program. With our full suite of in vivo and ex vivo capabilities, you can maximize the insights gained from the unique features of PDX models.

 

Oncology experience you can count on

With more than 10,000 studies completed, we have amassed extensive experience and deep insights to inform end-to-end discovery oncology research. Our team helps you explore the effects of drugs and biologics using both human and syngeneic tumor models providing you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. And if you are ready to move a lead candidate to IND/CTA and beyond, we have the unique ability to support you with testing throughout the entire development journey, anchored by a biomarker-driven strategy. With our experience, we help you gain efficiencies as we connect insights effectively from one stage to the next, empowering you to make more informed decisions every step of the way.

PDX FAQs

Patient-derived xenograft (PDX) models are cutting-edge tools in oncology research, derived from transplanting patient tumor tissues directly into immunocompromised mice. These models preserve the genetic, histological, molecular and spatial characteristics of the original human tumors including intratumor heterogeneity, offering a highly relevant platform for preclinical drug testing.

  1. Clinical relevance: PDX models closely mimic human tumors, including tumor heterogeneity, providing a superior model compared to traditional cell lines or genetically engineered models
  2. Predictive power: PDX models predict patient responses to therapies more accurately than other models, enabling researchers to prioritize drug candidates with higher potential for clinical success
  3. Personalized medicine: Each PDX model is derived from a specific patient's tumor, allowing for testing of therapies tailored to individual genetic and molecular profiles
  4. Study of resistance mechanisms: PDX models facilitate the study of drug resistance mechanisms by enabling longitudinal studies of tumor progression and response to treatment over time
  5. Long-term stability: PDX models can be passaged through multiple generations while maintaining the genetic and phenotypic stability of the original tumor, supporting longitudinal studies and reproducible results

Standard use includes, but is not limited to:

  • Preclinical evaluation of novel therapies (including cell therapy)
  • Validating novel drug combinations
  • Screening drug-sensitive patients (personalized medicine)
  • Exploring drug response/resistance mechanisms
  • Biomarker evaluation

Let's start a conversation